推荐产品
一般說明
Antibody molecules typically comprise two immunoglobulin light chains covalently bound to a pair of heavy chains. Immunoglobulin light chains occur in two types, designated by the Greek letters kappa and lambda. Kappa and lambda light chains are approximately 250 amino acids in length with an average mass of about 25 kDa. The ratio of kappa to lambda found in the immunoglobulin population varies by species.
特異性
Reacts with human lambda light chains. Absorbed for human myeloma proteins with kappa light chains.
The antibody reacts with human lambda light chains as demonstrated by ELISA and flow cytometry.
免疫原
Epitope: Ig lambda chain
Prepared from pooled antisera from goats hyperimmunized with human myeloma proteins with kappa light chains.
應用
Detect Human Ig λ chain using this Goat anti-Human Ig λ chain Antibody validated for use in ELISA.
Research Category
Secondary & Control Antibodies
Secondary & Control Antibodies
Research Sub Category
Fragment Specific Secondary Antibodies
Fragment Specific Secondary Antibodies
外觀
Affinity Chromatography
Purified by affinity chromatography on pooled human Igs with lambda light chains covalently linked to agarose. Liquid in 1.0 mL of 100 mM borate buffered saline, pH 8.2.
儲存和穩定性
Maintain refrigerated at 2°-8°C under sterile conditions for up to twelve months from date of receipt.
法律資訊
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
訊號詞
Danger
危險聲明
危險分類
Repr. 1B
儲存類別代碼
6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Kathrin Andrich et al.
The Journal of biological chemistry, 292(6), 2328-2344 (2016-12-30)
Intervention into amyloid deposition with anti-amyloid agents like the polyphenol epigallocatechin-3-gallate (EGCG) is emerging as an experimental secondary treatment strategy in systemic light chain amyloidosis (AL). In both AL and multiple myeloma (MM), soluble immunoglobulin light chains (LC) are produced
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门